Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Statement on Nuplazid Drug

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

The Parkinson’s Foundation is closely monitoring the recent reports on Nuplazid. At this time, we are recommending that patients on this drug consult with their neurologists about the risks and benefits of the treatment. The FDA will continue to monitor the drug’s use and safety, but they have not identified a specific safety issue that isn’t already described in the drug’s label. 

Parkinson’s disease psychosis is typically seen in advanced stages of Parkinson’s disease involving elderly patients. Treating Parkinson’s disease psychosis is a multi-step process that begins with talking to your health care team. They will follow a series of steps to figure out how best to address symptoms. For more information on this topic, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636). 

Please report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088. You can also call ACADIA Pharmaceuticals Inc. at 1‑844‑4ACADIA (1‑844‑422‑2342).

For more information about Psychosis and Parkinson’s Disease:

Listen to our podcast

Read our recent blog article

Read more in our free book, "Psychosis: A Mind Guide to Parkinson's Disease"

Watch our Expert Briefings: Parkinson's Disease Psychosis: Hallucinations, Delusions and Paranoia

Tuesday, April 10, 2018
The National Parkinson Foundation’s Moving Day® Walks Fund $1.25 Million in Parkinson’s Programs in 2015
Monday, December 14, 2015

MIAMI — The National Parkinson Foundation (NPF) is proud to announce that Moving Day®, A Walk for Parkinson’s, has funded $1.25 million in mission services in 2015 to make life better for people living with Parkinson’s.

The National Parkinson Foundation Answers 50,000 Helpline Calls
Monday, November 23, 2015

MIAMI — The National Parkinson Foundation (NPF) announced today that their toll-free Helpline, 1-800-4PD-INFO, has achieved a major milestone: the Helpline reached its 50,000th caller.

The Edmond J. Safra National Parkinson’s Wellness Initiative Expands to Chicago and Tampa
Tuesday, November 10, 2015

National Initiative to Improve the Quality of Life for People with Parkinson’s
 

The National Parkinson Foundation Awards Four Innovative Research Grants
Wednesday, November 4, 2015

One Million Dollar Investment in Clinical Research in Parkinson’s Disease

MIAMI — The National Parkinson Foundation (NPF) announced today that it has funded four new grants in Parkinson’s disease (PD) research. The four grants target key scientific questions about gender differences in Parkinson’s, cognition and inflammation.

Should Patients and Families Be Considering Tasigna (Nilotinib) Therapy for Parkinson’s Disease? The NPF Recommends Further Study but Not Clinical Use of this Investigational Drug
Wednesday, October 21, 2015

Tasigna (Nilotinib) is a leukemia drug that has recently been tested for safety in a small, phase I clinical trial on about a dozen Parkinson’s disease patients.

NatGeo to Air Live Parkinson's DBS Surgery: What Should You Know?
Tuesday, October 20, 2015

The Parkinson’s Disease Foundation (PDF) has learned that later this week, the National Geographic Channel will air a live television broadcast of deep brain stimulation surgery for Parkinson’s disease (PD).

Parkinson's Disease Foundation and American Parkinson Disease Association Collaborate to Cultivate Future Parkinson's Scientific Leaders
Thursday, October 15, 2015

The Parkinson's Disease Foundation® (PDF®) and the American Parkinson Disease Association (APDA) are pleased to announce their collaboration on Summer Student Fellowships to support research that will help solve, treat and end Parkinson's disease.

PDF Research Advocates Highlight Unmet Needs in Parkinson’s at FDA Meeting
Tuesday, September 29, 2015

The Parkinson’s Disease Foundation (PDF) is pleased to report that five of its Research Advocates represented the community at last week’s Food and Drug Administration’s (FDA) Patient-Focused Drug Development meeting on Parkinson’s Disease in Silver Spring, MD.

National Parkinson Foundation Ohio Chapter Now Serves Entire State
Monday, September 21, 2015

Moving Day® Cleveland, A Walk for Parkinson’s, Slated for June 2016

Columbus — The National Parkinson Foundation (NPF) Central & Southeast Ohio Chapter has officially changed its name to National Parkinson Foundation Ohio. The name change signifies the expansion of service statewide to the approximately 30-50,000 Ohioans with Parkinson’s disease (PD). 

Parkinson's Disease Foundation Mobilizes Community to Address Unmet Needs of Women Living with Parkinson’s
Wednesday, September 16, 2015

The Parkinson's Disease Foundation® (PDF®) is pleased to launch its Women and PD Initiative, the first national coordinated effort dedicated to improving the health and well-being of women living with Parkinson’s disease. The initiative launches this week with a three-day conference in Florham Park, NJ.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.